43 results about "Blood urate level" patented technology

The invention relates to euphausia superba peptide with uric acid reducing activity and application thereof. The euphausia superba peptide is a short peptide obtained by extraction, enzymolysis, separation and purification from degreased euphausia superba powder, and the amino acid sequence of the euphausia superba peptide is Ser-Ala-Gly-Lys-Thr. Researches show that the peptide can reduce the generation of uric acid by inhibiting the activity of xanthine oxidase and promote the excretion of uric acid. In-vitro cell experiments prove that under the concentration of 10 mu M, the inhibition rate of the peptide on xanthine oxidase reaches 23.1%; animal experiments show that the blood uric acid level of mice in a high-dose group (50mg / kg) is reduced by about 40% compared with that in a model group. The invention also develops a health-care beverage and a medicinal preparation which take the peptide as an active component, and provides a new choice for preventing and treating hyperuricemia and gout.

The invention discloses application of beta-alanine in preparation of a medicine for preventing and / or treating uric acid metabolic disorder related diseases. The invention provides a theoretical source of beta-alanine for reducing the uric acid level. In the earlier stage, the applicant of the invention adopts non-target metabolome and targeted metabolome data to construct a hyperuricemia prediction model, and Rmcorr correlation analysis shows that high beta-alanine level and low uric acid level have strong correlation. On the other hand, beta-alanine acid is adopted to intervene in a hyperuricemia mouse, it is proved that beta-alanine can reduce the blood uric acid level of the hyperuricemia mouse and promote urine uric acid excretion, and beta-alanine can be used for preventing and / or treating uric acid metabolic disorder related diseases.

The application relates to the technical field of traditional Chinese medicines, in particular to a uric acid reducing composition and a preparation method thereof. The uric acid reducing composition comprises 35-45 parts of a cyclodextrin inclusion compound, 25-35 parts of nano-liposomes, 20-30 parts of a chicory extract-phospholipid complex and 5-8 parts of an antioxidant complex; the preparation method of the cyclodextrin inclusion compound comprises the following steps: step 1, adding beta-cyclodextrin into water, stirring and dissolving, adding pueraria extract, drying after inclusion reaction, and obtaining inclusion compound a; step 2, adding hydroxypropyl-gamma-cyclodextrin into water, stirring, adding mulberry leaf extract, drying after inclusion, and obtaining inclusion compound b; and step 3, mixing the inclusion compound a and the inclusion compound b, and obtaining the product. The uric acid reducing composition can more comprehensively and efficiently reduce blood uric acid level, and has high safety, high stability and high bioavailability. The preparation method is simple, easy to industrialize and beneficial to large-scale industrial production.

The invention discloses a medicinal and edible composition for treating gout as well as a preparation method and application of the medicinal and edible composition, and belongs to the technical field of biological medicines. Comprising the following raw materials in parts by weight: 5-10 parts of honeysuckle, 5-10 parts of endive, 5-10 parts of galangal, 5-10 parts of bamboo fungus, 5-10 parts of alfalfa, 5-10 parts of gardenia, 5-10 parts of platycodon grandiflorum, 5-10 parts of sunflower seeds, 3-5 parts of cherries, 3-5 parts of blueberries, 3-5 parts of waxberries, 3-5 parts of Chinese wolfberry fruits, 2-3 parts of chrysanthemum, 2-3 parts of celery seeds, 2-3 parts of tricholoma matsutake, 2-3 parts of sparassis crispa, 2-3 parts of lotus leaves, 2-3 parts of hawthorn, 2-3 parts of dendrobium officinale and 2-3 parts of lucid ganoderma. Through reasonable compatibility of food-borne materials, the traditional Chinese medicine composition can well reduce the blood uric acid level, improve related inflammation indexes and relieve gout pain after being taken for a long time.

The application discloses application of total flavones of chrysanthemum morifolium ramat and metabolites thereof in preparation of uric acid-lowering or liver and kidney protecting drugs or health care products. The total flavones of chrysanthemum morifolium ramat contain various flavone compounds. In a hyperuricemia model mouse, the total flavones of chrysanthemum morifolium ramat can significantly reduce blood uric acid level, and has a significant protective effect on liver and kidney, and the effect is achieved by inhibiting the activity and expression of xanthine oxidase and adenosine deaminase in the liver, and regulating the expression of uric acid related transporters in the kidney. Meanwhile, metabolites of the total flavones of chrysanthemum morifolium ramat, luteolin-7-O-glucuronide and apigenin-7-O-glucuronide, can also play a pharmacological role in the mouse body. In vitro experiments and mouse primary hepatocytes further prove that luteolin-7-O-glucuronide and apigenin-7-O-glucuronide have an inhibiting effect on the activity and expression level of xanthine oxidase. The application widens the application range of traditional Chinese medicinal materials, and provides a new direction for development of efficient and low-toxic uric acid-lowering and anti-gout drugs or health care products.

The invention provides application of a roxburgh rose extract in preparation of a product for treating hyperuricemia and regulation and control of a purine metabolic pathway, and belongs to the technical field of biological medicines. The roxburgh rose aqueous extract extracted from roxburgh rose pomace can effectively intervene in hyperuricemia through a dual action mechanism: on one hand, the roxburgh rose aqueous extract significantly inhibits the expression of xanthine oxidase (XOD) in the liver, and reduces the generation of uric acid; on the other hand, expression of key urate transporters (including GLUT9, URAT1, ABCG2 and OAT1) is regulated and controlled, uric acid is promoted to be excreted through the kidney, and therefore the blood uric acid level is reduced in a synergistic mode, a solid theoretical basis and technical support are provided for developing a new HUA prevention and treatment strategy based on natural products, and a new thought is provided for prevention and treatment of hyperuricemia.

The invention provides a method for constructing an animal chronic gouty arthritis model, which comprises the following steps: a hyperuricemia model establishment stage: feeding a tested animal with a special feed containing oteracil potassium and yeast; establishing a chronic gouty arthritis model: repeatedly injecting urate into the tested animal; meanwhile, oteracil potassium is used for intragastric administration of the tested animal. On the basis of feeding with oteracil potassium combined with a special yeast feed, oteracil potassium solution is injected, blood uric acid level fluctuation is induced on the basis of blood uric acid increase, and urate crystals are injected repeatedly, so that the disease cause and pathological process of chronic gouty arthritis are simulated to the greatest extent; a chronic gouty arthritis animal model is successfully established by injecting urate crystals into joints of experimental animals repeatedly for a long time, inducing repeated attack of local acute inflammation of the joints and simulating pathological characteristics of chronic gouty arthritis.

The application discloses application of tomato saponin in preparation of a uric acid reducing composition and belongs to the technical field of biological medicine. The uric acid reducing composition comprises 80-240 parts of tomato saponin, 50-120 parts of momordica charantia saponin, 25-100 parts of fruit and vegetable extract, 10-20 parts of schizonepeta turczanovii extract, 10-20 parts of terminalia catappa leaf extract and 40-100 parts of soluble dietary mixture. Animal experiment verification shows that the composition can effectively reduce blood uric acid level and improve kidney function through the synergistic effect of multi-target points such as inhibition of uric acid synthesis, promotion of uric acid excretion, anti-inflammatory kidney protection and metabolic regulation, and a safe and efficient solution is provided for hyperuricemia.

The invention belongs to the technical field of traditional Chinese medicine preparations, and particularly relates to a traditional Chinese medicine composition for treating damp turbidity and blood stasis type hyperuricemia or gout and a preparation method and application of the traditional Chinese medicine composition. The traditional Chinese medicine composition comprises the following raw materials in parts by weight: 12-18 parts of radix paeoniae alba, 12-18 parts of yam rhizome, 45-55 parts of rhizoma smilacis glabrae, 25-35 parts of plantain herb, 8-12 parts of radix polygonati officinalis, 8-12 parts of radix cyathulae, 8-12 parts of fructus psoraleae, 7-11 parts of ground beeltle and 3-7 parts of liquorice. The traditional Chinese medicine composition is formulated according to the traditional Chinese medicine pathogenesis characteristics of hyperuricemia and gout, the whole formula takes improvement of intestinal mucosa barrier as the core, the effects of reducing the blood uric acid level, relieving symptoms and conditioning the body are achieved through diuresis promoting, turbidity removing, collateral dredging and blood stasis removing, and the traditional Chinese medicine composition is suitable for gout and hyperuricemia caused by intestinal damp turbidity and blood stasis blocking.

The application discloses a polypeptide with uric acid reducing activity and a preparation method and application thereof, relates to the field of bioactive peptides, and provides a preparation method of the polypeptide with uric acid reducing activity, which takes whey protein as raw material, and obtains the polypeptide with high activity through directional enzymolysis and ultrafiltration purification, and the polypeptide can reduce blood uric acid level by inhibiting xanthine oxidase activity, and the method has the advantages of high efficiency, low cost and easy implementation, can be implemented on a large scale, and is helpful to improving the utilization value of whey protein in the industry, and provides a new way for the development of functional natural anti-uric acid level abnormality or xanthine oxidase activity abnormality related disease products.

The present invention relates to a new application of fucoidan from sporophyll of Undaria pinnatifida, belonging to the technical field of food and medicine. The present invention provides a new application of fucoidan from sporophyll of Undaria pinnatifida in the preparation of drugs, health foods and foods for reducing uric acid, which can significantly reduce the level of blood uric acid, relieve and treat gout symptoms, has no toxic and side effects, is safe and effective, can be used for preparing URAT1 inhibitors and / or GLUT9 inhibitors, can be used for preparing health foods and foods for reducing uric acid, and can be used for preparing drugs for reducing uric acid and treating gout, and has broad application prospects.

The invention relates to the technical field of traditional Chinese medicines, in particular to a uric acid reducing composition and a preparation method thereof. The uric acid reducing composition is prepared from 35 to 45 parts of a cyclodextrin inclusion compound, 25 to 35 parts of nano-liposome, 20 to 30 parts of a chicory extract-phospholipid compound and 5 to 8 parts of an antioxidant compound, the preparation method of the cyclodextrin inclusion compound comprises the following steps: step 1, adding beta-cyclodextrin into water, stirring and dissolving, adding a radix puerariae extract, and drying after inclusion reaction to obtain an inclusion compound a; 2, hydroxypropyl-gamma-cyclodextrin is added into water, stirring is performed, the mulberry leaf extract is added, drying is performed after inclusion, and an inclusion compound b is obtained; and step 3, mixing the clathrate compound a and the clathrate compound b to obtain the compound. The uric acid reducing composition provided by the invention can be used for more comprehensively and efficiently reducing the blood uric acid level, and is high in safety, strong in stability and high in bioavailability. The preparation method is simple, convenient, easy to industrialize and beneficial to large-scale industrial production.

The invention relates to application of mannitol in preparation of drugs for reducing uric acid and / or preventing and treating gout kidney. The mass volume percentage of mannitol is 2-5%, and the mannitol in the concentration range can reduce the serum uric acid level by increasing urine uric acid excretion, reduce the uric acid content of the kidney tissue of a gout patient and reduce the serum urea nitrogen and creatinine content at the same time, so that the kidney tissue is protected. The invention further provides a pharmaceutical composition for reducing uric acid and / or preventing and treating gout kidney, which comprises the following components in percentage by mass volume: 2-5% of mannitol and 0.45-0.9% of sodium chloride. The invention provides new application of mannitol, the mannitol has dual effects of reducing the blood uric acid level and protecting the renal function, and a new treatment choice is provided for gout and gout kidney patients.

The invention relates to a traditional Chinese medicine composition for treating gout and a pill preparation thereof, the composition takes rhizoma smilacis glabrae and corn stigma as monarch drugs, Chinese actinidia root, fructus polygoni orientalis and the like as ministerial drugs, and erythrina bark, fructus viticis and the like as adjuvant drugs, and the synergistic effect of reducing uric acid and resisting inflammation is realized through scientific compatibility. Experiments show that the preparation can significantly reduce the blood uric acid level of gout model animals, inhibit ankle joint swelling and improve the symptoms of patients through clinical verification, and the safety is superior to that of a traditional western medicine scheme. The technical problems that an existing traditional Chinese medicine preparation is single in target spot and obvious in side effect are solved, and a new solution is provided for gout treatment.

The invention relates to the technical field of microorganisms and biological medicines, in particular to triple probiotics as well as a preparation method and application thereof, and the triple probiotics comprise at least one probiotic of bacillus, lactobacillus acidophilus and bifidobacterium longum. The triple probiotics provided by the invention form an'oxygen consumption-enzyme production-acid production 'synergistic chain, and through synergistic degradation of uric acid, inhibition of excessive growth of conditioned pathogens and enhancement of intestinal barrier functions, the blood uric acid level of patients with asymptomatic hyperuricemia is reduced, the alpha-diversity of intestinal tracts is improved, the abundance of butyric acid producing bacteria is improved, and the content of the butyric acid producing bacteria is improved. The ratio of escherichia coli to shigella is reduced; sIBO is effectively relieved or reversed, and digestive tract symptoms such as abdominal distension and exhaust are reduced. In addition, the triple probiotics avoid liver and kidney toxicity caused by chemical drugs, and are suitable for long-term administration.

The invention belongs to the technical field of traditional Chinese medicine modernization and medicine development, and particularly relates to a uric acid reducing product based on folium apocyni veneti extract and application of the uric acid reducing product. The core active component of the product is the folium apocyni veneti extract. In-vivo experiments prove that the extract can remarkably reduce the blood uric acid level and xanthine oxidase (XO) activity of a mouse with hyperuricemia. Six active ingredients entering blood are identified through in-vivo metabolism research. The direct interaction between the main active component and the target protein XO is verified from the molecular level through molecular docking, surface plasmon resonance (SPR) and isothermal titration calorimetry (ITC) technologies, and the uric acid reducing action mechanism of the compound is completely clarified. The invention provides a scientific basis and a high-quality product for developing a new uric acid-reducing drug effect of the folium apocyni veneti.

The present invention belongs to the technical field of foods and pharmaceuticals, and relates to a novel use of fucoidan of sporophylls of Undaria pinnatifida. Provided in the present invention is a novel use of fucoidan of sporophylls of Undaria pinnatifida in the preparation of drugs, health foods, and foods for lowering uric acid, which can significantly reduce blood uric acid levels, alleviate and treat gout symptoms, has no toxic side effects, is safe and effective, can be used in the preparation of a URAT1 inhibitor and / or a GLUT9 inhibitor, and can be used in the preparation of drugs, health foods, or foods for lowering uric acid and treating gout, and has broad application prospects.

The present invention belongs to the field of medicine, and specifically relates to a treatment method using mazdutide. The present invention provides a method for preventing or treating overweight and obesity, and a method for improving body weight in patients in need, the method comprising administering, to a patient in need, a prophylactically or therapeutically effective amount of a target compound in a dosage regimen comprising at least three dosing cycles. The present invention also provides a target compound, which is used for preventing or treating overweight or obesity in patients in need, wherein a prophylactically or therapeutically effective amount of the target compound is administered in at least three dosing cycles to a patient in need. The mazdutide dosage regimen provided has a remarkable weight reduction effect, noticeable weight reduction can be achieved with relatively low dosage in a relatively short amount of time, and blood pressure, blood lipid, and serum uric acid levels of a subject can simultaneously be improved.

The invention discloses an application of a hippocampus japonicus ethanol extract in preparation of a composition for reversing renal fibrosis. By reducing the blood uric acid level, improving the renal function and reversing the renal fibrosis pathology, a new drug choice is provided for treatment of HUA related renal fibrosis. The technical bottleneck that an existing uric acid reducing medicine reduces acid and does not block fibers is broken through, and the pharmaceutical composition has remarkable clinical transformation value and application prospects.

The invention discloses application of total flavonoids of chrysanthemum morifolium ramat and metabolites of the total flavonoids to preparation of medicines or health-care products for reducing uric acid or protecting liver and kidney. Wherein the chrysanthemum morifolium total flavonoids contain a plurality of flavonoid compounds. In hyperuricemia model mice, intragastric administration of the total flavonoids of Hangzhou white chrysanthemum can significantly reduce the blood uric acid level, and the total flavonoids of Hangzhou white chrysanthemum have significant protection effects on liver and kidney, and play a role in regulating and controlling the expression of kidney uric acid related transporters by inhibiting the activity and expression of xanthine oxidase and adenosine deaminase in the liver. Meanwhile, metabolites, namely luteolin-7-O-glucuronide and apigenin-7-O-glucuronide, of the Hangzhou white chrysanthemum general flavone in a mouse body can also play a pharmacological role. In-vitro experiments and mouse liver primary cells further prove that the luteolin-7-O-glucuronide and the apigenin-7-O-glucuronide have an inhibition effect on the activity and the expression level of xanthine oxidase. The application range of traditional Chinese medicinal materials is widened, and a new direction is provided for research and development of high-efficiency and low-toxicity uric acid-reducing and anti-gout medicines or development of health-care products.

The invention belongs to the technical field of pharmacy, and particularly relates to a rhizoma phragmitis sustained release preparation for hyperuricemia and a preparation method of the rhizoma phragmitis sustained release preparation. The reed rhizome sustained release preparation for hyperuricemia is prepared from the following raw materials in parts by weight: 80 to 100 parts of reed rhizome extract, 160 to 200 parts of functionalized reed rhizome powder, 0.01 to 0.1 part of freeze-dried powder, 40 to 65 parts of quercetin and 30 to 50 parts of acrylic resin, the rhizoma phragmitis extract and quercetin cooperate to comprehensively regulate uric acid metabolism; due to the introduction of the freeze-dried powder, real-time visual monitoring of in-vivo drug distribution and drug release progress is realized, and the targeting affinity of the preparation with intestinal mucosa and joint parts can be improved, so that the blood uric acid level quickly tends to be stable and is maintained for a long time; after the colon target positioning sustained-release pellet and the quercetin quick-release pellet are mixed, the quick-release pellet can be quickly disintegrated and release quercetin to realize quick acid control, and the sustained-release pellet can accurately deliver drugs in the colon and continuously release active ingredients to realize long-acting acid stabilization.

The present invention relates to a bacterial agent for alleviating hyperuricemia and its application. The bacterial strain in the bacterial agent for alleviating hyperuricemia is Akkermansia muciniphila. Akkermansia muciniphila Akk09 strain and Bifidobacterium animalis subsp. lactis Bifidobacterium animalum subsp. milk The two strains are composed of the BLa80 strain. They complement and enhance each other, synergizing their effects in alleviating hyperuricemia, specifically by lowering blood uric acid levels; inhibiting xanthine oxidase activity; reducing urea nitrogen and creatinine levels; alleviating kidney inflammation and oxidative stress caused by hyperuricemia; and regulating intestinal flora disturbances caused by hyperuricemia.

The invention relates to a bacterial agent for relieving hyperuricemia and an application of the bacterial agent. The bacterial strain in the bacterial agent for relieving the hyperuricemia is composed of an Ackermania muciniphila Akk09 bacterial strain and a Bifidobacterium animalis subsp. Lactis BLa80 bacterial strain, and the bacterial strain in the bacterial agent for relieving the hyperuricemia is composed of an Akkermania muciniphila Akk09 bacterial strain and a Bifidobacterium animalis subsp. Lactis BLa80 bacterial strain. The two strains can cooperate with each other and promote each other, and have a synergistic effect on the aspect of relieving hyperuricemia, specifically, the level of blood uric acid is reduced; the activity of xanthine oxidase is inhibited; the urea nitrogen and creatinine levels are reduced; kidney inflammation and oxidative stress caused by hyperuricemia are relieved; the intestinal flora disorder caused by high uric acid is regulated.

The present invention relates to the technical field of food processing, and particularly to a compound fermented cereal formula food and its application that can be used for blood sugar control, fat reduction and weight loss. The compound fermented cereal prepared by the present invention can effectively inhibit the activities of α-amylase and α-glucosidase, control fasting blood glucose and dyslipidemia; it can also promote the growth of the intestinal probiotic Akkermansia muciniphila (AKK bacterium), regulate the F / B value, effectively reduce body weight and abdominal fat, reduce the level of blood uric acid, improve liver function; alleviate the damaging effect of diabetes and high-fat and high-sugar diet patterns on the pancreas; and has the advantages of wide sources of preparation raw materials, low cost, safety and high efficiency. Further, the compounding of the compound fermented cereal and chlorogenic acid in the present invention can significantly improve the inhibitory activities against α-amylase and α-glucosidase, especially the inhibitory activity against α-glucosidase, which can be increased by up to 1.7 times compared with using chlorogenic acid alone.

The application discloses a traditional Chinese medicine composition for treating hyperuricemia and gout, a preparation method and application thereof, and can effectively reduce blood uric acid level, relieve gouty arthritis, and has good analgesic effect, and the curative effect is better than that of a commonly used western medicine in clinic; raw materials used are low in price, and the preparation process is simple, so that the medicine cost is greatly reduced. The traditional Chinese medicine composition for treating hyperuricemia and gout is prepared from the following raw materials in parts by weight: Huangqi 3-12 parts by weight, Huanglian 1.5-6 parts by weight, Huangbai 1.5-6 parts by weight, Zhizi 2-8 parts by weight, Chaihu 3-12 parts by weight, Lianqiao 2-8 parts by weight, and Baishao 2-8 parts by weight.

The invention discloses a traditional Chinese medicine composition for treating hyperuricemia as well as a preparation method and application of the traditional Chinese medicine composition. The traditional Chinese medicine composition is prepared from semen hoveniae, radix puerariae, semen phaseoli, raw fructus gardeniae, herba taraxaci, poria cocos and rhizoma dioscoreae. According to the traditional Chinese medicine composition, dissolution of effective components is improved through a combined mode of decocting radix puerariae first and decocting other medicines together, dialectical components are adopted, whole-course intervention of upstream generation inhibition, midstream dissolution and crystallization and downstream excretion promotion on hyperuricemia metabolic disorder can be achieved, and the effect of treating hyperuricemia metabolic disorder can be achieved through physique conditioning, heat clearing and diuresis promoting, spleen strengthening and kidney tonifying, detoxification and turbid descending, collateral dredging and blood stasis dissipating. The blood uric acid level and inflammation balance are successfully recovered to a physiological state, and the action mode is superior to a traditional single uric acid reducing strategy and a traditional Chinese medicine application mode of decocting the whole formula simultaneously. In an animal model, the composition has the effects of remarkably reducing uric acid, regulating inflammation, protecting kidney and improving overall physique, the curative effect of a high-dose group is equivalent to that of a classic uric acid reducing medicine allopurinol, and the composition has more advantages in the aspects of kidney pathological repair and long-term safe conditioning.

A postbiotic extract of Lactobacillus plantarum CB102 is prepared by the steps of: subjecting the Lactobacillus plantarum CB102 to a protein extraction treatment, so as to obtain a protein extract; and subjecting the protein extract to a hydrolysis treatment with a protease, so as to obtain the postbiotic extract of Lactobacillus plantarum CB102. The Lactobacillus plantarum CB102 is deposited at the Leibniz Institute DSMZ-German Collection of Microorganisms and Cell Cultures GmbH under an accession number DSM 33894 in accordance with the Budapest Treaty. A method for preparing a postbiotic extract of Lactobacillus plantarum CB102, and methods for reducing a blood uric acid level and alleviating a uric acid metabolism-associated disorder using the postbiotic extract of Lactobacillus plantarum CB102 are also provided.

The invention discloses a traditional Chinese medicine composition for treating chronic refractory gout. The traditional Chinese medicine composition is prepared from the following raw material medicines in parts by weight: 10-15 parts of astragalus membranaceus, 15-20 parts of rhizoma smilacis glabrae, 6-10 parts of earthworm, 6-10 parts of radix angelicae pubescentis, 10-15 parts of radix clematidis, 3-6 parts of honey-fried licorice root, 6-10 parts of angelica sinensis, 10-15 parts of white hyacinth bean, 6-10 parts of curcuma zedoary, 10-15 parts of white paeony root and 10-15 parts of roasted malt. The traditional Chinese medicine composition can significantly reduce the blood uric acid level, improve the symptoms of traditional Chinese medicine and reduce the recurrence frequency of gout, has a potential protection effect on renal functions, and provides a safe and effective new scheme for treatment of chronic refractory gout.

The invention discloses a traditional Chinese medicine formula for treating gout, and belongs to the field of traditional Chinese medicines. The traditional Chinese medicine formula comprises the following raw materials by mass: 20-40g of rhizoma smilacis glabrae, 20-40g of semen coicis, 5-20g of radix cyathulae, 5-20g of cortex phellodendri, 10-30g of rhizoma dioscoreae septemlobae, 10-40g of rhizoma imperatae, 5-25g of cornu bubali, 5-15g of radix stephaniae tetrandrae The rhizoma smilacis glabrae is used as a monarch drug, the rhizoma smilacis glabrae can clear away heat and toxic materials, dredge joints, inhibit generation of uric acid and promote excretion of uric acid, and the semen coicis and rhizoma dioscoreae septemlobae are matched to inhibit generation of uric acid in multiple ways, promote excretion of uric acid in multiple channels, relieve crystallization inflammation and reduce the blood uric acid level. The lalang grass rhizome is used for cooling blood and stopping bleeding, the buffalo horn is used for removing heat and cooling blood, resisting inflammation and easing pain, and the radix stephaniae tetrandrae is used for dispelling wind and eliminating dampness, so that through compatibility of the lalang grass rhizome, the buffalo horn and the radix stephaniae tetrandrae, joint swelling and pain can be remarkably relieved, pain is eased and inflammation is resisted, and a traditional Chinese medicine formula capable of regulating purine metabolism, inhibiting uric

The invention discloses a traditional Chinese medicine composition for treating animal gout and application of the traditional Chinese medicine composition, and belongs to the technical field of animal medicine. The core active components of the traditional Chinese medicine composition comprise astilbin, tanshinone IIA and tetrahydrocurcumin, wherein the preferable mass ratio of all the components is 4: 1: 3. Pharmacodynamic studies show that the composition has a significant synergistic effect, can effectively reduce the blood uric acid level of animals with hyperuricemia, and synergistically inhibits the activity of xanthine oxidase (XOD). Compared with existing chemical drugs, the pharmaceutical composition disclosed by the invention has the advantages that through synergistic combination of the drugs, the toxic and side effects and the possibility of drug resistance are effectively reduced while the concentration of uric acid is efficiently reduced, a safe, efficient and economic brand-new scheme is provided for treating animal gout, and the pharmaceutical composition has important application value.